GSK seeks to expand low platelet drug Promacta to hepatitis C patients

GlaxoSmithKline (NYSE:GSK) now wants approval to use its low platelet drug Promacta to treat hepatitis C patients. GSK has filed regulatory applications in Europe and the United States to add the new…
Read the full story: MedCity News